2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4f0,Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer. Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms. Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 ( Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.31:Tb25, PURPOSE Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer. PATIENTS AND METHODS Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash–Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms. RESULTS Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 ( P = .02), and 6.89 ( P < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 ( P = .07), and 13.95 ( P = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg ( P = .042) and 5 mg ( P < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo. CONCLUSION Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"oxybutynin: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on oxybutynin (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/oxybutynin\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"oxybutynin\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/oxybutynin\"}]}}"}}]],["$","$L2f",null,{"title":"oxybutynin: Research & Clinical Takeaways","description":"Explore research on oxybutynin (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1002/pros.70229","pmid":"42542970","title":"Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy","journal_title":"The Prostate","journal_issn":"0270-4137","published_at":"2026-08-02T00:00:00.000Z","url":"https://doi.org/10.1002/pros.70229","source_score":12,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-06T13:22:03.101Z","updated_at":"2026-08-06T13:22:03.101Z","tags":[{"paper_doi":"10.1002/pros.70229","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"condition","value":"Hot Flashes","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"generic","value":"clonidine","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"generic","value":"cyproterone acetate","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"generic","value":"fezolinetant","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"generic","value":"gabapentin","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"generic","value":"oxybutynin","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Acupuncture","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Alpha-2 Agonist","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Androgen Deprivation Therapy","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Antiandrogen","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Anticholinergic","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Cognitive Behavioral Therapy","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Estrogen","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Gabapentinoid","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Progestogen","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"modality","value":"Selective Serotonin Reuptake Inhibitor","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"sample_size","value":"n=35","value_numeric":35},{"paper_doi":"10.1002/pros.70229","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"warning","value":"Fezolinetant is mentioned only as a future research direction; no efficacy data in this population are available from this review.","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"warning","value":"Level of evidence set to 2 based on systematic review design; individual included studies likely vary widely in quality and design.","value_numeric":null},{"paper_doi":"10.1002/pros.70229","tag_type":"warning","value":"Sample size tag reflects the number of included studies (n=35), not individual patients — total patient numbers are not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Systematic review of pharmacological and non-pharmacological interventions for hot flashes in men with prostate cancer undergoing androgen deprivation therapy (ADT), based on 35 studies identified from a PubMed search of 469 papers.","key_result":"Across all blinded pharmacological trials, hot flash frequency fell by 21%–84% (placebo effect: 19%–30%). Hormonal agents (cyproterone acetate, estrogen/derivatives) showed the greatest efficacy; acupuncture and CBT offered modest benefit; dietary supplements (Dong Quai, soy protein, Salvia officinalis, Serelys Homme) appeared ineffective.","limitations":"- Only 35 of 469 papers were included, and the overall evidence base is limited in size and quality.\n- The review does not include newer agents like fezolinetant, which have not yet been evaluated in this population.\n- Study heterogeneity in outcomes (frequency vs. quality of life) limits direct comparisons across interventions.","practice_takeaway":"For men on ADT troubled by hot flashes, hormonal agents (cyproterone acetate or estrogen) are the most effective options but carry side effect risks — discuss these trade-offs with patients. Acupuncture or CBT are reasonable non-hormonal alternatives; routine use of dietary supplements is not supported."}},{"doi":"10.1200/jco-25-01486","pmid":"41587370","title":"Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-01-26T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-01486","source_score":223,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-02","doi":"10.1200/jco-25-01486","days":"14","issn":"0732-183X","rank":"1","field":"Clinical Medicine","score":"223","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1200/JCO-25-01486","title":"Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","methods":"","results":"Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 (","abstract":"$30","keywords":[],"pubmed_id":"41587370","conclusions":"Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.","publication_date":"2026-01-26T00:00:00"},"crossref":{"DOI":"10.1200/jco-25-01486","URL":"https://doi.org/10.1200/jco-25-01486","ISSN":["0732-183X","1527-7755"],"link":[{"URL":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-01486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1198-1205","type":"journal-article","issue":"13","score":1,"title":["Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer"],"author":[{"given":"Bradley J.","family":"Stish","sequence":"first","affiliation":[{"name":"Mayo Clinic Department of Radiation Oncology, Rochester, MN"}]},{"given":"Gina L.","family":"Mazza","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Scottsdale, AZ"}]},{"given":"Jones T.","family":"Nauseef","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Weill Cornell Medicine; Sandra and Edward Meyer Cancer Center, New York, NY"}]},{"given":"Michael Sandon","family":"Humeniuk","sequence":"additional","affiliation":[{"name":"Gibbs Cancer Center, Spartanburg Regional Healthcare System, Spartanburg, SC"}]},{"given":"Thomas J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD"}]},{"given":"Cindy","family":"Tofthagen","sequence":"additional","affiliation":[{"name":"Mayo Clinic Division of Nursing Research, Jacksonville, FL"}]},{"given":"Dayssy Alexandra","family":"Diaz Pardo","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}]},{"given":"Christopher","family":"Chay","sequence":"additional","affiliation":[{"name":"SCOR—Messino Cancer Centers, Ashville, NC"}]},{"given":"Andrew J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Aspirus Regional Cancer Center, Wausau, WI"}]},{"given":"Kushal","family":"Naha","sequence":"additional","affiliation":[{"name":"MU Health—University Hospital/Ellis Fischel Cancer Center, Columbia, MO"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Division of Hematology & Medical Oncology, Weill Cornell Medicine; Sandra and Edward Meyer Cancer Center, New York, NY"}]},{"given":"Selina","family":"Chow","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, University of Chicago, Chicago, IL"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, MN"}]},{"given":"Maryam B.","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Yale University, New Haven, CT"}]},{"given":"Lucile L.","family":"Adams-Campbell","sequence":"additional","affiliation":[{"name":"Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC"}]},{"given":"Paul J.","family":"Novotny","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, MN"}]}],"issued":{"date-parts":[[2026,5,1]]},"member":"233","prefix":"10.1200","source":"Crossref","volume":"44","created":{"date-time":"2026-01-26T20:59:09Z","timestamp":1769461149000,"date-parts":[[2026,1,26]]},"indexed":{"date-time":"2026-05-01T07:54:10Z","timestamp":1777622050994,"date-parts":[[2026,5,1]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://ascopubs.org/doi/10.1200/JCO-25-01486"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-23"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2025-10-15"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-12-18"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-26"}],"deposited":{"date-time":"2026-04-28T22:00:18Z","timestamp":1777413618000,"date-parts":[[2026,4,28]]},"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"published":{"date-parts":[[2026,5,1]]},"publisher":"American Society of Clinical Oncology (ASCO)","reference":[{"DOI":"10.1634/theoncologist.8-5-474","key":"e_1_3_11_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/aja.2011.101","key":"e_1_3_11_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.urolonc.2009.09.004","key":"e_1_3_11_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0277-9536(97)00058-0","key":"e_1_3_11_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ctro.2018.03.002","key":"e_1_3_11_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.31024","key":"e_1_3_11_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3109/13697137.2015.1125460","key":"e_1_3_11_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/pon.3150","key":"e_1_3_11_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/pon.3448","key":"e_1_3_11_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJM199408113310602","key":"e_1_3_11_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(09)70338-9","key":"e_1_3_11_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdn644","key":"e_1_3_11_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/01.gme.0000243574.01441.3e","key":"e_1_3_11_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/GME.0000000000000773","key":"e_1_3_11_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/jncics/pkz088","key":"e_1_3_11_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc1801992","key":"e_1_3_11_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2307/2529712","key":"e_1_3_11_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0885-3924(01)00353-0","key":"e_1_3_11_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2012.48.1432","key":"e_1_3_11_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamainternmed.2014.1891","key":"e_1_3_11_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/01.AOG.0000147840.06947.46","key":"e_1_3_11_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"U.S. National Library of Medicine. MedlinePlus-Oxybutynin Drug Information. U.S. National Library of Medicine. 2024. https://medlineplus.gov/druginfo/meds/a682141.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_11_24_2","year":"2000","issue":null,"author":"Versi E","volume":"95","first-page":"718","unstructured":"Versi E, Appell R, Mobley D, et al: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 95:718-721, 2000","article-title":"Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group","journal-title":"Obstet Gynecol","doi-asserted-by":null},{"DOI":"10.1016/j.eururo.2006.03.057","key":"e_1_3_11_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2013.01.002","key":"e_1_3_11_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1532-5415.1998.tb01006.x","key":"e_1_3_11_27_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/gme.0b013e31819c46c7","key":"e_1_3_11_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,5,1]]}},"update-policy":"https://doi.org/10.1200/crossmark","alternative-id":["10.1200/JCO-25-01486"],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Clinical Oncology"],"published-print":{"date-parts":[[2026,5,1]]},"reference-count":27,"published-online":null,"references-count":27,"short-container-title":["J Clin Oncol"],"is-referenced-by-count":2},"unpaywall":{"doi":"10.1200/jco-25-01486","is_oa":false,"title":"Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer","updated":"2026-01-28T14:16:39+00:00","published_date":"2026-01-26","best_oa_location":null}},"created_at":"2026-05-07T22:51:17.517Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1200/jco-25-01486","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"condition","value":"Hot Flashes","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"generic","value":"oxybutynin","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"modality","value":"Anticholinergic Agent","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"sample_size","value":"n=81","value_numeric":81},{"paper_doi":"10.1200/jco-25-01486","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"warning","value":"No long-term follow-up data beyond 6 weeks are available; durability of hot flash relief and delayed adverse effects (e.g., cognitive effects of anticholinergics) are unknown.","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"warning","value":"Published date is January 2026; today is May 2026 — paper is recently published and may not yet be reflected in clinical guidelines.","value_numeric":null},{"paper_doi":"10.1200/jco-25-01486","tag_type":"warning","value":"The trial enrolled only 88 patients (81 analyzed), which limits statistical power for subgroup analyses and AE detection. The impact_flag 'practice_changing' is applied cautiously given the small sample size and short follow-up; larger confirmatory trials would strengthen this designation.","value_numeric":null}],"summaries":{"what_studied":"A randomized, placebo-controlled trial (Alliance A222001) evaluated oxybutynin 2.5 mg BID vs. 5 mg BID vs. placebo over 6 weeks in men with prostate cancer on stable ADT who had ≥28 hot flashes/week (n=81 eligible).","key_result":"Both oxybutynin doses outperformed placebo: reductions in hot flashes/day were 4.77 (2.5 mg, P=.02) and 6.89 (5 mg, P<.001) vs. 2.15 with placebo; HFRDIS scores improved by 14.2 and 20.7 points vs. 3.1 with placebo; no treatment-related grade 3+ adverse events occurred.","limitations":"Small sample size (n=81 in final analysis); short 6-week follow-up limits conclusions about durability of benefit or long-term safety; study limited to men, so findings may not generalize broadly.","practice_takeaway":"Consider oxybutynin (especially 5 mg BID) as an effective, well-tolerated option for managing ADT-induced hot flashes in men with prostate cancer. The 5 mg dose offered the largest symptom reduction with no grade 3+ treatment-related side effects over 6 weeks."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"oxybutynin"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"oxybutynin"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"oxybutynin"}}}]]

Papers